Emergency Department, Dandenong Hospital, David Street, Dandenong, Vic. 3101, Australia.
Emerg Med Australas. 2010 Dec;22(6):507-13. doi: 10.1111/j.1742-6723.2010.01346.x.
To compare the change in visual analogue scale (VAS) pain ratings over 24 h following mechanical corneal abrasion between patients receiving sixth hourly drops of either 5% homatropine or placebo.
A triple blind randomized controlled trial was conducted on a convenience sample of eligible consenting adults who were randomized to receive either sixth hourly 5% homatropine (active) or 0.5% hypromellose (placebo) eye drops. VAS pain ratings were performed at 0, 6, 12, 18 and 24 h whereas the study drug was instilled at 0, 6, 12 and 18 h. The primary outcome was attainment of a clinically significant reduction in pain on the VAS (>20 mm decrease) from enrolment to each time point.
There were no significant differences in baseline variables or VAS pain ratings at any time point between those in the homatropine (n= 20) and placebo (n= 20) groups. The percentages of patients reporting a >20 mm VAS decrease at 12 h were 50% (95% CI -27.2-72.8) and 60% (95% CI -36.1-80.9) for the homatropine and placebo groups, respectively.
We found no significant difference in pain score reductions between the two groups but some level of therapeutic benefit is not excluded.
比较接受每 6 小时滴注 5%阿托品或安慰剂的机械性角膜擦伤患者在 24 小时内视觉模拟量表（VAS）疼痛评分的变化。
对符合条件的成年患者进行了一项三盲随机对照试验，将其随机分为接受每 6 小时滴注 5%阿托品（活性）或 0.5%羟丙甲纤维素（安慰剂）的患者。在 0、6、12、18 和 24 小时时进行 VAS 疼痛评分，而在 0、6、12 和 18 小时时滴注研究药物。主要结局是从入组到每个时间点 VAS 疼痛评分（>20mm 下降）达到临床显著缓解。
在基线变量或任何时间点的 VAS 疼痛评分方面，阿托品组（n=20）和安慰剂组（n=20）之间没有显著差异。在 12 小时时报告 VAS 下降>20mm 的患者比例分别为 50%（95%CI-27.2-72.8）和 60%（95%CI-36.1-80.9）。
我们发现两组之间疼痛评分降低没有显著差异，但不能排除一定程度的治疗益处。
